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ZNF750 is a lineage-specific tumour suppressor in squamous
cell carcinoma
M Hazawa1,2,6, D-C Lin1,3,6, H Handral4, L Xu1, Y Chen1, Y-Y Jiang1, A Mayakonda1, L-W Ding1, X Meng1, A Sharma1, S Samuel1,
MM Movahednia4, RW Wong2, H Yang1, C Tong4 and HP Koeffler1,3,5
ZNF750 controls epithelial homeostasis by regulating epidermal-differentiation genes, a role underscored by its pathogenic
mutations in esophageal squamous cell cancers (SCCs). However, the precise role of ZNF750 in SCC cell biology remains unclear. In
this study, we report that ZNF750 is exclusively deleted, mutated and underexpressed in human SCCs, and low ZNF750 expression
is associated with poor survival. Restoration of wildtype, but not mutant ZNF750 protein uniquely inhibited the malignant
phenotypes of SCC cells both in vitro and in vivo. Notably, ZNF750 promoted the expression of a long non-coding RNA (TINCR),
which mediated both cancer-inhibition and differentiation-induction effects of ZNF750. In addition, ZNF750 potently suppressed
cell migration by directly inhibiting the transactivation of LAMC2. Together, our findings characterize ZNF750 as a crucial SCC-
specific suppressor and uncover its novel anticancer-associated functions.
Oncogene (2017) 36, 2243–2254; doi:10.1038/onc.2016.377; published online 7 November 2016
INTRODUCTION
Squamous cell carcinoma (SCC) is the most common human cancer.
It arises from stratified epithelia, including the oral epithelium,
epidermis and the epithelia covering the oesophagus, bladder, vulva
and cervix. Approximately 300 000 new SCC cases per year occur in
the United States alone, resulting annually in ~100 000deaths.1,2
Recently, we and others identified missense and truncating
mutations as well as genomic deletions targeting ZNF750 in
esophageal SCC (ESCC).3,4 Functionally, we have shown that loss of
ZNF750 was associated with impaired differentiation as well as a
failure to repress tumour growth in ESCC,3 suggesting that ZNF750
may act as a tumour suppressor. ZNF750 was reported to function as
a transcriptional regulator of epidermal cell differentiation by
inducing differentiation genes while inhibiting progenitor factors.5
However, the precise role of ZNF750 in SCC cells largely remain
unexplored. Particularly, the molecular events and signalling path-
ways associated with ZNF750 in SCCs await further characterization.
Long non-coding RNAs (LncRNAs) have recently been reported
to participate in the regulation of epidermal cell differentiation.
For example, the LncRNA TINCR promotes differentiation of
keratinocytes through a mechanism involving direct RNA:RNA
interactions and recruitment of STAU1 protein to stabilize
differentiation-specific mRNAs.6 Another recent report demon-
strated lncRNA/transcription factor network, which regulated
epidermal differentiation.7 However, whether and how these
differentiation-associated LncRNAs are involved in the biology of
SCC cells have not been fully addressed.
In this study, we demonstrate that ZNF750 is frequently and
exclusively targeted by genetic lesions in major types of human
SCCs, including those cancers of the cervix (CSCC), head and neck
(HNSCC) and lung (LSCC). Low expression level of ZNF750 is
associated with poor prognosis of SCC patients. Furthermore, the
tumour-suppressive role of ZNF750 is mediated through regulat-
ing key cancer genes such as TINCR and LAMC2.
RESULTS
ZNF750 is exclusively mutated, deleted and under-expressed in
different types of human SCCs
To determine comprehensively the genetic abnormalities affect-
ing ZNF750, multiple public datasets were re-analysed, including
The Cancer Genome Atlas (TCGA), Gene Expression Omnibus
(GEO) and Human Protein Atlas (see Materials and Methods). In
TCGA whole-exome sequencing results, similar to our earlier
findings in ESCC,3 a number of mutations throughout ZNF750
were identified in various SCC types, including CSCC, HNSCC and
LSCC (Figure 1a). Of note, most of these somatic variants occurred
at the beginning of Exon 2, which encodes for the evolutionally
conserved C2H2 DNA-binding domain, highlighting the biologic
relevance of this domain in SCC cells (Figure 1a). In addition, many
of the mutations caused damaging effects to the ZNF750 protein
(for example, Stopgain, Frameshift and Splicing mutations). We
next compared ZNF750 gene dosage between tumour and normal
samples using SNP 6.0 array data from TCGA, and found
significant genomic deletions of ZNF750 in primary SCC samples
from cervical, head and neck, and lung tissues (Figure 1c).
Importantly, these genetic abnormalities were exclusively
observed in squamous-type tumours (Figure 1c), underscoring
the lineage-specific role of ZNF750 in squamous cancer biology.
Next, in order to examine ZNF750 expression across different
types of normal and cancer tissues at both mRNA and protein
levels, we queried GEO cDNA microarray data (series GSE7307),
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TCGA RNA-seq data, as well as immunohistochemistry (IHC) results
from Human Protein Atlas (see Materials and Methods). Notably,
expression of both ZNF750 mRNA and protein was markedly
higher in a variety of healthy squamous epithelium than non-
squamous tissues, again signifying its lineage-specific expression
pattern and function (Figures 2a and b). Moreover, results from
GEO (series GSE9750 and GSE25099) and Human Protein Atlas
showed significantly decreased ZNF750 expression compared to
its normal counterpart at both mRNA (Supplementary Figure 1)
and protein levels (Figure 2c) in CSCC and HNSCC. Congruent with
these publically available data, we performed IHC analysis to stain
samples from CSCC, HNSCC and LSCC (commercial tissue array,
see Materials and Methods), and confirmed either lower or
undetectable ZNF750 expression in tumour tissues (Figure 2d).
Notably, Kaplan–Meier analysis on the TCGA cohorts revealed that
the downregulation of ZNF750 was significantly correlated with
poorer outcome of patients with HNSCC and LSCC (Log-rank test,
P= 0.04 and 0.01, respectively, Figure 2e). Collectively, these
findings suggest that ZNF750 is uniquely compromised by
multiple forms of genomic defects in human SCCs.
As a p63-dependent transcription factor, ZNF750 regulates KLF4
expression in SCC cells
ZNF750 was recently identified as a p63-downstream transcription
factor, and activated KLF4 transcription in normal keratinocyte;5
however, these regulations in the context of cancer cells are
unknown. In order to investigate these transcriptional regulations
in SCCs, we first depleted p63 using shRNA and confirmed that
ZNF750 expression was decreased at both the mRNA and protein
levels as addressed by qRT-PCR and western blot analysis
(Figures 3a and b). We next analysed p63 and ZNF750 protein
levels in a panel of different types of SCC cell lines (Figure 3c). The
abundance of p63 protein tended to have positive correlation
with that of ZNF750 in 10 SCC cell lines tested (Figure 3d).
Concordantly, analysis of 86 squamous cancer cell lines in Cancer
Cell Line Encyclopedia (CCLE) datasets showed a significant linear
correlation between the mRNA levels of ZNF750 and p63
(Supplementary Table 1 and Figure 3e). We further observed a
positive correlation between the levels of ZNF750 and p63
transcripts exclusively in squamous-type primary tumours based
on TCGA RNA-seq datasets (Figure 3f).
Next, we sought to determine whether ZNF750 controls KLF4
expression in SCC cells. Upregulation of KLF4 transcript level was
observed in ZNF750 over-expressing SCC cells (Figure 3g); in
contrast, KLF4 mRNA expression decreased in ZNF750 depleted
cells (Figure 3h). Notably, the level of KLF4 was positively
correlated with ZNF750 expression in SCC cell lines (Figure 3i).
Consistently, we found a linear correlation between the mRNA
levels of ZNF750 and KLF4 in CSCC, HNSCC and LSCC patient
samples from TCGA RNA-seq datasets (Figure 3j). Collectively,
these data suggested that ZNF750 is p63-dependent factor and
regulates KLF4 expression in SCCs.
Tumour-suppressive property of ZNF750 in SCC cells
To explore the biological relevance of ZNF750 in SCCs, cell line
models with ectopic ZNF750 expression were established.
Previous studies found that the evolutionarily conserved atypical
C2H2 zinc finger motif was required for its transactivation in
normal keratinocyte;5,8 therefore, we performed functional analy-
sis with wildtype as well as C2H2 mutant ZNF750 in a number of
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Figure 1. ZNF750 is exclusively disrupted in squamous cell carcinomas. (a) Analysis of ZNF750 somatic mutations in CSCC, HNSCC, LSCC from
TCGA (see URL). Results in ESCC were summarized from published studies.3,4 Different types of mutations and their location and frequency are
shown. (b) Location of ZNF750 mutations in CSCC, HNSCC, LSCC and ESCC. (c) Summary of ZNF750 mutations across different tumour types
from TCGA. Numbers in the parentheses indicate the number of cases sequenced. CSCC/EA, CSCC and endocervical adenocarcinoma; CA,
colorectal adenocarcinoma; BIC, breast invasive carcinoma; LA, lung adenocarcinoma; BLGG, brain lower grade glioma; AML, acute myeloid
leukemia; PA, prostate adenocarcinoma; GM, glioblastoma multiforme; OSC, ovarian serous cystadenocarcinoma; TC, thyroid carcinoma; UC,
uterine carcinosarcoma.
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cell lines from either CSCC, skin SCC, HNSCC or LSCC. Exogenous
wildtype ZNF750 expression resulted in significant reduction in
short-term cell proliferation (Figure 4a and Supplementary Figures
2a and b). In contrast, C2H2 mutant partially or fully lost its
inhibitory effect on cell proliferation (Figure 4a). Similarly, wildtype
ZNF750, but not C2H2 mutant inhibited foci formation in a variety
of SCC cells (Figures 4b and c). The tumour-suppressive potential
of ZNF750 was further evaluated by xenograft tumour formation.
Importantly, wildtype ZNF750 robustly suppressed tumour growth
compared with the control group, whereas the C2H2 mutant had
significantly less suppressive ability in vivo (Figure 4d). In addition,
Ki-67 staining by IHC of xenograft tumours supported our findings
that ZNF750 protein decreased the proliferative cell population
(Figure 4e). Moreover, the well-defined differentiation marker
Involucrin (IVL) was highly expressed in tumours expressing
wildtype ZNF750 (Figure 4e). Not surprisingly, neither ZNF750
wildtype nor C2H2 mutant affected p63 expression both in vivo
and in vitro (Supplementary Figures 2c and d). Unaltered
p63 transcript level was also observed in ZNF750 depleted
cells (Supplementary Figure 2e), in agreement with earlier
results5 showing that ZNF750 was downstream of p63
(Figures 3a and b).
We next addressed whether ZNF750 regulates other important
malignant phenotypes. Notably, wildtype ZNF750 potently
inhibited the migration of different types of SCC cells. In sharp
contrast, the C2H2 mutant expressing cells showed minimal effect
on migration (Figure 4f). We next determined cell adhesion by
measuring the efficiency of SCC cells to adhere to collagen type I,
and found that this cellular phenotype was significantly impaired
by wildtype ZNF750, but was unaffected by the C2H2 mutant
(Figure 4g). As cellular signalling during cell adhesion is associated
with anoikis resistance,9 we examined the effect of ZNF750
on resistance to anoikis of SCC cells (Figures 4h and i). Concor-
dantly, we attenuated anoikis-resistance only in wildtype ZNF750
but not C2H2 mutant cells. We confirmed that impaired
tumour-suppressive functions of the C2H2 mutant was not
due to the lack of expression or mis-localization (Supplemen-
tary Figures 2f and g). Importantly, ZNF750 hardly affected
proliferation in non-SCC cells such as glioblastoma cells
(Supplementary Figures 2h and i). Taken together, these data
strongly suggest that ZNF750 is a bona fide lineage-specific
tumour suppressor, and the C2H2 domain is important for its
biological functions in SCCs.
Transcriptome analysis of ZNF750-regulated genes and processes
To explore how ZNF750 suppressed SCC cell malignancy, we
performed both cDNA microarray and whole transcriptome
sequencing (RNA-seq) to measure global alterations in mRNA
levels upon ZNF750 restoration. Gene ontology (GO) analysis
revealed that ZNF750 activated a subset of genes highly enriched
in processes regulating terminal epidermal differentiation similar
to the function of ZNF750 in normal keratinocytes (Figure 5a).
Notably, genes repressed by ZNF750 were significantly enriched in
processes highly relevant to cancer biology, including cell
migration, proliferation, adhesion and cell death, all of which
were shown to be regulated by ZNF750 in our experiments
(Figure 4). Gene set enrichment analysis (GSEA) further confirmed
that ZNF750-upregulated genes were associated with an ‘epider-
mal late differentiation signature’7 (Figure 5b) while ZNF750-
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Figure 2. ZNF750 is under-expressed in squamous cell carcinomas. (a) ZNF750 mRNA expression across normal tissues examined from GEO
(series GSE7307). Data show mean± s.d. (b) ZNF750 protein expression across normal tissues from Human Protein Atlas (see URL). IHC was
performed using anti-ZNF750 antibody (HPA021573, Sigma-Aldrich, St Louis, MO, USA). (c) Representative IHC photos (left panel) and IHC
scores (right panel) of ZNF750 protein expression in CSCC and HNSCC from Human Protein Atlas. IHC was performed using anti-ZNF750
antibody (HPA023012, Sigma-Aldrich). (d) In-house IHC assay of ZNF750 expression in CSCC, HNSCC and LSCC samples. Normal tissues are
from cervical tissues (×10 magnification). (e) Low ZNF750 expression (mRNA expression z-Scores (RNA Seq V2 RSEM)4mean+1.8 SD or 2.0 SD)
was associated with poor disease-free survival of HNSCC and LSCC patients in the TCGA cohorts.
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Figure 3. ZNF750 is a p63-dependent transcription factor and controls KLF4 expression in SCCs. (a) qRT-PCR analysis of ZNF750 mRNA in SCC
cells following p63 depletion. Data show mean± s.d. N= 3. *Po0.05. (b) Western blot analysis of ZNF750 levels in p63-silenced SCC cells. (c, d)
Western blot analysis (c) and co-expression analysis (d) of p63 and ZNF750 protein (40 μg/lane) levels in various SCC cell lines. (e) Co-
expression analysis of ZNF750 mRNA and p63 mRNA in 86 squamous-type cell lines from CCLE (see URL). (f) Summary of correlation
coefficients between ZNF750 mRNA and p63 mRNA across different tumour types from TCGA datasets. (g, h) qRT-PCR analysis of KLF4 mRNA
in ZNF750 overexpressed SCC cells (g) and ZNF750 depleted SCC cells (h). Data show mean± s.d. N= 3. *Po0.05. (i) Co-expression analysis of
KLF4 mRNA and ZNF750 protein (40 μg/lane) levels in various SCC cell lines. (j) Co-expression analysis of ZNF750 and KLF4 mRNA based on
TCGA dataset. r; spearman score.
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repressed genes were enriched in an ‘epidermal progenitor
signature’7 (Figure 5b).
LncRNAs have been shown to participate in the regulation of
epidermal cell differentiation. To determine whether ZNF750
could regulate the expression of epidermis differentiation-related
LncRNAs, we cross-compared LncRNAs whose levels were
changed upon ZNF750 activation to those with differential
expression during epidermal differentiation6 (Figure 5c). Interest-
ingly, we identified TINCR as a candidate ZNF750-promoted
LncRNA.
Many epidermal progenitor genes contribute to the malignant
phenotype of cancer cells, such as uncontrolled proliferation,
enhanced migration, EMT and so on.10 Thus, we hypothesized that
ZNF750-mediated repression of epidermal progenitor genes
might account for its tumour-suppressive functions in SCC cells,
which we observed (Figure 4). We performed similar cross-
comparisons, and nominated a total of seven genes as possible
ZNF750-repressed progenitor factors, namely THBS1, CTNNAL1,
FST, LAMC2, NT5E, NRG1 and COL12A1 (Figure 5d).
ZNF750 drives epidermal differentiation in SCCs
Our transcriptome analysis showed that epidermal differentiation
was the most significantly enriched process activated by ZNF750
in SCC cells. Therefore, the role of ZNF750 in differentiation
regulation in SCCs was further characterized. We first validated
that wildtype ZNF750 induced the epidermal differentiation
complex11 including the small proline-rich proteins 1B (SPRR1B),
the calcium-binding protein S100A8 and IVL (Figure 6a and
Supplementary Figure 3a), while suppressing the expression of the
basal cell marker K14 in a variety of SCC cells (Figure 6b).
Confirmation of the pro-differentiation function of ZNF750 was its
ability to enhance the level of IVL protein both under organotypic
and 2D culture conditions (Figure 6c, and Supplementary Figures
3b and c). Importantly, these changes were only triggered
by wildtype but not C2H2 mutant ZNF750 (Figures 6a–c).
Concordantly, ablation of endogenous ZNF750 either by siRNA-
mediated knockdown or CRISPR/Cas9-mediated genomic disrup-
tion decreased the expression of these differentiation factors
(Figures 6d and e, and Supplementary Figures 3d and e).
Furthermore, interrogation of TCGA RNA-seq datasets showed a
linear correlation between the mRNA levels of ZNF750 and
epidermal differentiation-related genes in CSCC, HNSCC and LSCC
patient samples (Figure 6f). These positive correlations were
exclusively observed in squamous-type tumours in TCGA RNA-seq
datasets (Figure 6g), again underscoring the lineage-specific role
of ZNF750 in cancer biology. We next asked whether differentia-
tion stimuli lead to changes of the level of ZNF750. Consistently,
stimuli of keratinocyte differentiation, including high confluence
condition12 or Ca2+ concentration,8 caused marked induction of
ZNF750 expression (Figure 6h and Supplementary Figure 3f).
Collectively, these results suggest that ZNF750 strongly promotes
Figure 4. Tumour-suppressive properties of ZNF750 in SCCs. (a–c) Short-term proliferation assay (MTT) (a), foci formation assay (b) and the
quantification of SCC cell growth (c) either with ectopic expression of GFP control (CTL), wildtype or C2H2 mutant ZNF750. Data show
mean± s.d. N= 3. *Po0.05. (d) UMSCC1 cells expressing indicated vectors (upper panel) were injected subcutaneously on the upper flanks of
NOD-SCID mice, and tumour weights were measured. Data represent mean± s.d. *Po0.05. (e) Representative samples of Ki67 and IVL
expression detected by IHC in dissected xenograft tumours. (f–g) SCC cells expressing indicated vectors were subjected to migration assay (f)
and adhesion assay (g). Data show mean± s.d. N= 3 (f) and 4 (g). *Po0.05. (h-i), Dead cells (trypan-blue positive) (h) and cleaved-PARP (i) in
SCC cells expressing indicated vectors upon anoikis challenge. Data show mean± s.d. N= 4 (h). *Po0.05.
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epidermal differentiation through induction of a number of
differentiation-related factors in various types of SCC cells.
To determine further whether ZNF750 regulates the differentia-
tion of non-malignant cells, such as keratinocytes, the expression
levels of epidermal differentiation factors were measured in HaCaT
(non-malignant keratinocytes13) by qRT-PCR after siRNA-mediated
ZNF750 depletion (Figure 6i). Indeed, differentiation genes
were suppressed in ZNF750 silenced HaCaT cells (Figure 6i),
highlighting the role of ZNF750 in enabling epidermal
differentiation.
ZNF750 regulation of TINCR LncRNA mediates differentiation, cell
growth and cell migration in SCCs
TINCR was identified as a ZNF750-regulated LncRNA; however, its
roles in the settings of SCC are unknown. We next sought to
understand whether and how TINCR is involved in the biology of
SCCs and its relationship with ZNF750. In order to define the
regulation between TINCR and ZNF750, we first confirmed the
upregulation of TINCR transcripts in ZNF750 over-expressing SCC
cells (Figure 7a), and the downregulation of TINCR in ZNF750
depleted cells (Figure 7b). Of note, TINCR transcript levels were
significantly correlated with ZNF750 protein levels in SCC cell lines
(Figure 7c). Moreover, transcripts of both TNCR and ZNF750 are
activated during epidermal lineage induction (unpublished data)
(Figure 7d). Furthermore, we observed a positive correlation
between the levels of ZNF750 and TINCR transcripts exclusively in
squamous-type tumours on TCGA RNA-seq datasets (Figures 7e
and f), suggesting that ZNF750 can activate both LncRNAs (such as
TINCR) and coding genes in SCCs.
Next, to explore the role of TINCR in SCC biology, we asked
whether TINCR regulates SCC cell malignancy. Depletion of TINCR
by siRNA resulted in an increased cell growth as well as migration
activity (Supplementary Figures 4a–c). Moreover, silencing of
TINCR resulted in the decrease of differentiation-related gene
(Supplementary Figure 4d). We next probed whether TINCR was
involved in ZNF750-mediated functions. Importantly, TINCR
depletion partially rescued ZNF750-repressed malignancies,
including cell growth (Figures 7g and h) and migration
(Figure 7i). Silencing of TINCR also impaired the activation of
differentiation-related gene by ZNF750 (Figure 7j). In addition,
Kaplan–Meier analysis revealed that low levels of TINCR were
significantly correlated with poor outcome of patients with HNSCC
(Log-rank test, P= 0.03) in the TCGA cohort (Figure 7k). Collec-
tively, these results strongly suggest that as one of the down-
stream targets of ZNF750, TINCR mediates the tumour-suppressive
function of ZNF750 in SCC cells.
GO terms for ZNF750-activated genes
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Figure 5. Transcriptome analysis of ZNF750-regulated genes and processes. (a) GO analysis of ZNF750-activated and -repressed genes
measured by RNA-seq comparing cells over-expressing GFP versus ZNF750 protein. (b) GSEA of ZNF750-induced genes versus indicated gene
signatures. (c) Venn diagram illustrating the overlap between LncRNAs regulated by ZNF750 in UMSCC1, and the ones with differential
expression patterns during epidermal differentiation reported by Kretz et al.6 (d) Venn diagram illustrating the overlap between ZNF750-
dependent repressed genes and epidermal progenitor signature genes reported by Vanessa et al.7
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Transcriptional repression of LAMC2 by ZNF750 in SCC cells
LAMC2 is one of the seven candidate progenitor genes repressed
by ZNF750 (Figure 5d). We and others previously have shown that
LAMC2 promoted the proliferation and migration of several types
of cancer cells.14–19 Thus, we hypothesized that transcriptional
repression of LAMC2 by ZNF750 might partially account for its
tumour-suppressive activities. To determine whether ZNF750
regulates LAMC2 at the transcriptional level, we measured the
levels of LAMC2 transcript and protein upon forced expression of
either wildtype or C2H2 mutant ZNF750 (Figures 8a and b). LAMC2
expression was robustly decreased by wildtype but not C2H2
mutant ZNF750. A recent study found that ZNF750 interacted with
target genes through recognizing the ‘CCNNAGGC’ DNA motif.8
Thus, we searched for this motif near the transcription starting site
of LAMC2, and identified it within regions of R2, R3, R4 (Figure 8c).
R1 region that does not contain the motif was prepared as a
negative control. ChIP-PCR results showed a prominent binding of
ZNF750 to the R2 region (Figure 8d). To examine if this DNA
region is responsible for ZNF750-mediated transcriptional regula-
tion of LAMC2, dual-reporter luciferase assay was performed
(Figure 8e). Importantly, wildtype ZNF750 strongly suppressed the
luciferase activity of R2 in 293 T cells (Figure 8e). These data
indicate that ZNF750 directly inhibits the transcription of LAMC2
in SCC cells.
We next asked whether LAMC2 was involved in ZNF750-
regulated cell migration. Depletion of LAMC2 inhibited cell
migration (Supplementary Figures 5a and b), whereas over-
expression of LAMC2 enhanced this process (Supplementary
Figures 5c and d). Rescue experiments showed that re-
introduction of LAMC2 in cells over-expressing ZNF750 signifi-
cantly elevated the impaired cells’ migration (Figures 8f and g).
Taken together, these results strongly suggest that ZNF750
suppresses SCC cell migration by directly inhibiting LAMC2
transcription.
DISCUSSION
In this study, we demonstrated genomic and expression
abnormalities and biological relevance of ZNF750, which is
exclusive in human SCCs. Interestingly, TINCR LncRNA participated
in control of cellular proliferation, migration and differentiation
downstream of ZNF750. Furthermore, ZNF750 suppressed migra-
tion of SCC cells by directly inhibiting transactivation of LAMC2.
Genome instability is one of the hallmarks of cancer, and
somatic mutation and copy number loss are major causes of the
inactivation of tumour suppressors. Based on our genomic analysis
in three major types of human SCCs (CSCC, HNSCC and LSCC),
4.5% of ZNF750 mutations lead to detrimental frameshifts or pre-
mature truncations of ZNF750 protein. In addition, many
Figure 6. ZNF750 regulates epidermal differentiation in a variety of SCC cells. (a) qRT-PCR analysis of differentiation related genes and (b) basal
cell marker K14 gene in SCC cells expressing indicated vectors. Data show mean± s.d. N= 3. *Po0.05. (c) Western blot analysis of IVL and K14
levels in SCC cells expressing indicated vectors. (d) qRT-PCR analysis of differentiation related genes in SCC cells treated with either scrambled
siRNAs (siCTL) or ZNF750 siRNAs (siZNF750). Data show mean± s.d. N= 3. *Po0.05. (e) Western blot analysis of IVL and K14 levels in SCC cells
treated with indicated siRNA. (f) Co-expression analysis of ZNF750 mRNA and epidermal differentiation gene mRNA based on TCGA dataset. r;
spearman score. (g) Summary of correlation coefficient between the mRNA levels of ZNF750 and indicated differentiation genes across
different tumour types from TCGA. (h) Western blot analysis of ZNF750 protein levels in SCC cells under proliferative condition (cellso50%
confluent) (P) or differentiation condition (super confluent) (D) in vitro. (i) qRT-PCR analysis of differentiation related genes including KLF4 in
non-SCC cell line HaCaT treated with scrambled siRNAs (siCTL) or ZNF750 siRNAs (siZNF750). Data show mean± s.d. N= 3. *Po0.05.
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mutations were identified within the first 100 amino acids, which
encodes for the evolutionally conserved C2H2 DNA-binding
domain. We functionally validated that mutation of this domain
resulted in its loss of function. A recent report studying normal
keratinocytes also demonstrated that mutation of the C2H2
destroyed the ability of ZNF750 to activate differentiation genes.5,8
Moreover, a cancer-derived mutant, ZNF750 S70X, caused
mislocalization and abrogated its tumour suppressing function in
ESCC.4 Collectively, these data suggest that somatic mutations
compromise ZNF750 function during tumorigenesis.
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We further confirmed the downregulation of ZNF750 expression
in these SCCs, which is consistent with its expression profiles in
ESCC.3,4 We also report, for the first time, the prognostic value of
ZNF750 expression in all major SCCs, highlighting the biological
relevance of ZNF750 in these malignancies.
Tumour differentiation is an important clinical-pathological
parameter affecting malignant potential.10,20 Here, we showed
that restoration of ZNF750 in SCCs cells activated a number of
epidermal differentiation genes such as IVL, SPRR1B and S100A8.
Importantly, these differentiation-related genes have been shown
to be functionally relevant in SCCs. For example, S100A8/S100A9
were recently reported to inhibit G2/M progression and cell
growth through enhancing PP2A phosphatase activity in HNSCC
cells.21 In addition, S100A8/S100A14 inhibited the oncogenic
function of HPV16 E7 protein through regulating Casein Kinase II-
dependent phosphorylation of E7.22 Thus, ZNF750-regulated
differentiation genes not only serve as markers of cellular
differentiation but also modulate SCC cellular functions.
We found that TINCR LncRNA mediates biological functions
downstream of ZNF750. Recently, Kretz et al reported decreased
TINCR expression in human SCC samples,6 implying that TINCR has
a tumour-suppressive role. However, oncogenic functions of TINCR
through inhibiting KLF2 in gastric cancer was also observed
recently.23 Endogenous levels of KLF2 are undetectable in SCCs
(unpublished data); therefore, the cancer-related function of TINCR
might be context-dependent requiring further investigation.
In summary, we show that somatic inactivation and decrease
expression of ZNF750 contributes to the pathogenesis of SCC, and
that ZNF750 expression is a novel biomarker for SCC prognosis.
Through a variety of detailed mechanistic studies, both TINCR and
LAMC2 were identified as functional downstream factors of
ZNF750. These data will shed light on the understanding of the
molecular basis of SCC biology.
MATERIALS AND METHODS
Cell culture
HEK293T (kindly provided by Dr Yoshiaki Ito, Cancer Science Institute of
Singapore), CSCC cell lines (C33A, CaSki, HT-3, ME180 and SiHa), skin SCC
(SCC13), HNSCC cell lines (UMSCC1 and 93UV147) (kindly provided by Dr
Timothy Chan, Memorial Sloan Kettering Cancer Center), and a sponta-
neously immortalized human keratinocyte cell line (HaCaT, kindly provided
by Dr Norbert Fusenig, German Cancer Research Centre) were maintained
in Dulbecco’s Modified Eagle Medium supplemented with 10% (vol/vol)
fetal bovine serum and 1% (vol/vol) penicillin/streptomycin (P/S), and LSCC
cell lines (Calu-1, ChagoK1, H2170 and H226, kindly provided by Dr GOH
Boon Cher, Cancer Science Institute of Singapore) were maintained in
RPMI1640 supplemented with 10% fetal bovine serum and 1% P/S, at
37 ºC, 5% CO2 in a humidified atmosphere. Cell lines were recently tested
for the absence of mycoplasma. Cell lines were authenticated by short
tandem repeat analysis with the Geneprint 10 System Kit (B9510, Promega,
Madison, WI, USA) in 2014.
Cell proliferation assay
SCC cells were seeded into a 96-well plate at 3000 cells/well and cultured
for the indicated time courses. Cell viability was assessed using the MTT
(3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide) method.
In brief, 10 μL of 12 mM MTT solution was added into each well followed
by 3 h incubation, which was stopped by adding 100 μL of STOP solution
(2% acetic acid, 16% SDS, 42% DMF). Samples were mixed thoroughly and
measured at 570 nm for absorbance.
Foci formation assay
SCC cells were seeded into six-well plates at 1000 cells/well and cultured
for 10 days, followed by fixation, staining with crystal violet and
photographing the cells. For quantification, staining was dissolved in
MTT stop solution, and measured at 570 nm for absorbance.
Migration assay
SCC cells were seeded onto transwell inserts (3422, Corning, Kennebunk,
ME, USA) in 24-well plates and incubated for 48 h. The inserts were washed
with PBS, and non-migrating cells were wiped off the top side. Migrated
cells were fixed with 4% paraformaldehyde, stained with 4′,6-diamidino-2-
phenylindole (DAPI), and nuclei were counted.
Adhesion assay
Ninety-six-well tissue culture plates were coated with COL-I at 37 °C for 1 h
and rinsed with PBS. SCC cells were added to each well, and cells were
allowed to incubate at 37 °C for 30 min. After washing, adherent cells were
estimated by MTT method described earlier.
Western blotting
Cells were lysed with lysis buffer (20 mM HEPES (pH 7.4), 350 mM sodium
chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 10% (v/v) glycerol, 1%
Triton X-100, a mixture of protease inhibitors (Roche, Indianapolis, IN, USA),
0.2 mmol/L sodium orthovanadate and 1 mmol/L phenylmethylsulfonyl
fluoride). BCA assay (Santa Cruz, Dallas, TX, USA) was used for protein
quantification. Cell lysates or immunoprecipitation elutes were subjected
to SDS-PAGE followed by conventional wet transfer. Membranes were
incubated with antibodies as indicated and exposed to secondary
horseradish peroxidase-conjugated antibodies (Millipore, Billerica, MA,
USA). Antibodies used in this study were listed in Supplementary Table S2.
The relative amount of p63 and ZNF750 protein was quantified by
densitometry using Photoshop CS6 Extended (Adobe, San Jose, CA, USA)
and normalized by GAPDH. Values from each cell line were then divided by
that of UMSCC1.
Tissue micro array and IHC
Human cervix cancer tissue array (OD-CT-RpUtr03-006, 30 normal cervical
tissues and 30 CSCC tissues), head and neck tissue array (HN803c, 64
HNSCC tissues), and lung SCC tissue array (LC1505, 49 LSCC tissues) were
obtained from US Biomax Inc. (Rockville, MD, USA). In the IHC experiment,
the slides were deparaffinized and blocked with goat serum for 30 min at
room temperature, followed by incubation with rabbit anti-ZNF750 (1:50;
HPA023012, Sigma-Aldrich, St Louis, MO, USA) overnight at 4 ºC. After
incubation with horseradish peroxidase-linked secondary antibody (Dako,
Tokyo, Japan) for 60 min, slides were counterstained with Mayer’s
hematoxylin. The degree of immunostaining was viewed and scored
Figure 7. LncRNA TINCR mediates the function of ZNF750. (a) qRT-PCR analysis of TINCR in SCC cells either with ectopic expression of GFP
control (CTL) or wildtype ZNF750 and (b) in ME180 cells (CSCC) transfected with either scrambled siRNAs (siCTL) or ZNF750 siRNAs (siZNF750).
Data show mean± s.d. N= 3–6. *Po0.05. (c) Co-expression analysis of TINCR transcripts and ZNF750 protein (40 μg/lane) levels in variety of
SCC cell lines. (d) Human H1 embryonic stem cells were differentiated to keratinocyte progenitors in vitro, and the global RNA expression
profile during differentiation were analysed using RNA-seq. Sequencing reads after normalization spanning ZNF750 gene are shown.
Numbers indicate FPKM value (Fragments Per Kilobase of Exon per Million Fragments Mapped). (e) Co-expression analysis of ZNF750 mRNA
and TINCR transcripts from TCGA dataset. (f) Summary of correlation coefficient between ZNF750 mRNA and TINCR transcripts across different
tumour types from TCGA dataset. (g) SCC cells expressing either GFP (CTL, control) or wildtype ZNF750 were transfected with either scrambled
or TINCR siRNAs and then subjected to foci formation assay (representative photos), and (h) foci were quantified. Data show mean± s.d. N= 4.
*Po0.05. (i) SCC cells with indicated treatment were subjected to migration assay. (j) Effects of TINCR knockdown on differentiation-related
gene expression; heatmaps show average fold change measured by qRT-PCR (N= 3). (k) Low TINCR expression is associated with poor disease-
free survival of HNSCC patients on TCGA cohort.
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separately by two independent investigators without any prior knowledge
of clinicopathologic data. Expression of ZNF750 was scored as either
absent, weak (faint staining in o25% of tumour cells), medium (moderate
staining in 25–o75%) or high (moderate staining in 75%).
cDNA vectors, shRNA vectors and siRNAs
Expression vectors pLEX-ZNF750 (wildtype) and pLEX-C2H2 mutant
ZNF750 (C2H2 mutant) were generously provided by Dr Paul A. Khavari
(Stanford University School of Medicine). We also used another ZNF750
expression vector, SHC003-ZNF750 (which we reported previously3), in
some of the experiments to confirm that the results were not affected by
different vector systems (Supplementary Figure 6). The shRNA construct for
p63 was made with PLKO.1 backbone (Sigma-Aldrich) using Age I and EcoR
I sites (Supplementary Table S3). LAMC2 over-expression and shRNA
vectors were described previously.24 Pooled siRNAs targeting human
ZNF750 (M-014417-01) and TINCR (R-015725-00-0005) and scramble siRNA
(D-001210-01) were purchased from Thermo Scientific (Rockford, IL, USA)
(Supplementary Table S3).
Transfections, viral particle production and infection
DNA and siRNA transfections were performed using Lipofectamine 2000 and
Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA, USA), respectively.
Lentiviral particles were produced with the MISSION Lentiviral Packaging
System (Sigma-Aldrich). SCCs cells were transduced with the lentiviral particles
in the presence of 8 μg/ml polybrene (Sigma-Aldrich) for 48 h.
cDNA preparation and quantitative real-time RT-PCR assay
Quantitative real time RT-PCR was performed by KAPA SYBR qPCR kits
(KAPA Biosystems, Wilmington, MA, USA) in a 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s
instructions. The relative mRNA expression level of target genes was
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Figure 8. ZNF750 represses LAMC2 transactivation. (a) qRT-PCR analysis of LAMC2 mRNA levels in SCC cells expressing indicated vectors. Data
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calculated using GAPDH as a loading control. The primers are listed in
Supplementary Table S4.
Xenograft growth assay
Female, 5–6 weeks, non-obese diabetic severe combined immunodeficient
(NOD-SCID) mice were randomly allocated to control and experimental
cohorts. Eight mice were used for control cohort; six and five mice were
used for wildtype and C2H2 mutant groups, respectively. Three million
UMSCC1 cells transduced with GFP (Control), wildtype or C2H2 mutant
were mixed with 100 μl of Matrigel (BD Biosciences, San Jose, CA, USA) and
injected subcutaneously in the upper flanks of the NOD-SCID mice. After
5 weeks, mice were euthanized; tumours were dissected and weighted. No
blinding of investigators was performed. No statistical methods were used
to determine the sample size of mice. The experiment was performed in
compliance with ethical regulations of the Institutional Animal Care and
Use Committee of the National University of Singapore.
Chromatin Immuno-precipitation (ChIP) assay
Formaldehyde was used to cross-link proteins to DNA. Cells were lysed
with buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA. 0.1 mM
EGTA, 0.5% NP-40). Nuclei were pelleted at 12 000 rpm for 5 min and lysed
in 800 μl lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS). Cell
lysates were sonicated using a Bioruptor ultrasonic cell disruptor to shear
genomic DNA to an average fragment size of 150–250 bp, and
immunoprecipitation was performed using Chip-grade HA antibody
(ab9110, Abcam, Cambridge, MA, USA). One microgram of primary
antibody/10 million cells was incubated with precleared chromatin for
16 h. Protein A/G dynabeads were added for 1 h and followed with
increasing stringency washes with cold low salt wash buffer, high salt wash
buffer, LiCl wash buffer and TE buffer. Bound DNA was eluted by the buffer
containing 1% SDS and 0.1 M NaHCO3, reverse-crosslinked overnight at
65 °C, purified using a QIAquick PCR purification kit (QIAGEN, Hilden,
Germany). The primers used for PCR amplification of the precipitated DNA
fragments are R1 forward 5′-GATTCACCCATGCTGTGTATGT-3′, R1 reverse
5′-CCTTTAATTAACACATGGCTTTTCA-3′; R2 forward 5′-CAAGCCTGAGCCA
GACAGTT-3', R2 reverse 5′-CCACCAGCAGCCTCTTTTAT-3′; R3 forward 5′-C
ACCAACTGCAAGCTAGATACTATT-3′, R3 reverse 5′-GACGAGGTCTTGCTG
TGTTG-3′; R4 forward 5′-TAACCCTGGTGAGCAGGAAG-3′, R4 reverse 5′-C
TCCGGCTTAAAGGACATCA-3′.
Reporter assay
Four individual fragments (R2: nucleotide (nt) − 2506/− 2273 was cloned
from UMSCC1 cells into pGL3 vector using multi-cloning sites (XhoI/MluI).
Primer pairs for cloning are XhoI-R2 forward 5′-AAAACGCGTGGA
GCAAGGTAAGGGAT-3′ and MluI-R2 reverse 5′-TTTCTCGAGCGCAGCAAAT
GGGCACA-3′.
The Dual Luciferase Reporter Assay system (Promega) was used
according to the manufacturer’s instructions. In brief, 293 T cells were
seeded into 24-well plates and co-transfected with pGL3-R2, pRL-TK, plus
either GFP or wildtype ZNF750. After 48 h, the levels of renilla and
luciferase activity was measured.
Bioinformatics and data analysis
Copy number data of various SCC types including CSCC, HNSCC and LSCC
were collected from TCGA (see URL) via cBio Cancer Genomics Portal (see
URL) and analysed by IGV software (see URL). Somatic mutation profiles of
ZNF750 in ESCC were obtained from previous reports by Lin et al and
Zhang et al.3,4 (Figures 1a and b). Mutation and deletion results of ZNF750
across various cancers were from TCGA (Figure 1c). ZNF750 mRNA
expression in normal tissues were examined based on GEO (see URL,
GSE7307) (Figure 2a). ZNF750 mRNA-expression and survival data in
HNSCC and LSCC were obtained from TCGA via cBio Cancer Genomics
Portal (Figure 2e). Spearman correlation values were analysed through
TCGA via cBio Cancer Genomics Portal (Figures 3f and j, Figures 6f and g,
Figures 7e and f). ZNF750 protein expression levels were obtained from
Human Protein Atlas (Figures 2b and c). Expression profiles of ZNF750 and
p63 in squamous cancer cell lines were determined based on CCLE (see
URL) (Figure 3e). TINCR expression and survival data in HNSCC were from
TCGA via The Atlas of ncRNA in Cancer (Figure 7k). All datasets were
accessed and analysed by 1 July 2015. GO analysis was performed using
ConsensusPathDB (see URL). GSEA was performed with GSEA v2.2.2
software (see URL).
Statistical analyses
The following experiments (cell proliferation assay, anchorage-dependent
colony formation assay, migration assay, adhesion assay, anoikis assay, real
time RT-PCR analysis and luciferase reporter assay) were performed in
triplicate (n=3) and independently replicated three or four times. Data
were shown as average of biological replicates (N= 3 or 4). Two-tailed
Student’s t-test was performed upon verification of the assumptions (for
example, normality), otherwise the non-parametric test was applied by
GrafPad Prism. We performed correlation analysis and calculated Pearson
correlation value using GrafPad Prism. Po0.05 was considered statistically
significant.
URLs
The Cancer Genome Atlas (TCGA), http://cancergenome.nih.gov/; Inte-
grated Genomics Viewer (IGV), http://www.broadinstitute.org/igv; cBio
Cancer Genomics Portal, http://www.cbioportal.org/; Human Protein Atlas,
http://www.proteinatlas.org/; Gene Expression Omnibus (GEO), http://
www.ncbi.nlm.nih.gov/geo/; The Atlas of ncRNA in Cancer (TANRIC),
http://ibl.mdanderson.org/tanric/_design/basic/index.html; Cancer Cell
Line Encyclopedia (CCLE), http://portals.broadinstitute.org/ccle/; Gene Set
Enrichment Analaysis (GSEA), http://software.broadinstitute.org/gsea; Con-
sensusPathDB, http://consensuspathdb.org/.
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